The advantage of allogenicity when using Inflammatory dendritic cells as antitumor immune primersPublished: July 4, 2019
Cellular Immuno-Oncology 4.0
Sharon Longhurst, Juliana Kovacka, Emilia Heimann, Margareth Jorvid, Sijme Zeilemaker, Peter Suenaert & Alex Karlsson-Parra
For an allogeneic somatic cell therapy to become commercially successful in the field of oncology, where the patient population is significantly large, there needs to be an abundant supply of starting material, and the final product should be presented in a ready to use format that is available immediately, with no need to coordinate final stages of production with patient treatment schedules. Ideally the product should evade or modulate the immune system to avoid alloreactivity impacting on product efficacy, and the final cost of goods should be a low as is feasibly possible to ensure a cost-effective treatment. The allogeneic inflammatory dendritic cell product, ilixadencel, ticks a number of these boxes. The advantages of ilixadencel from a clinical and manufacturing perspective are discussed, as well as challenges that will need to be appropriately addressed to ensure future commercial success.DOI: 10.18609/cgti.2019.043
Citation: Cell & Gene Therapy Insights 2019; 5(5), 383-398.